Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Meghara K. Walsh"'
Autor:
Neeraj Agarwal, Judit Kocsis, Charles P. Theuer, Mohamed Darif, Jing Lyu, Sumanta K. Pal, Bonne J. Adams, Mollie deShazo, Kouros Owzar, Thai H. Ho, Toni K. Choueiri, Liz Robertson, Yousef Zakharia, Andrew B. Nixon, Meghara K. Walsh, Russell K. Pachynski, Lajos Géczi, Yingmiao Liu, Alexandr Poprach, Primo N. Lara, Mark D. Starr
Publikováno v:
The oncologist, vol 26, iss 7
Oncologist
Oncologist
Lessons Learned Background Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb3cefb1fe953ed4cc21558dbfb65ff
https://escholarship.org/uc/item/6xc9d29b
https://escholarship.org/uc/item/6xc9d29b
Autor:
Daniel J. George, Joel Picus, Olwen Hahn, Darren R. Feldman, Shaker R. Dakhil, Meghara K. Walsh, Susan Halabi, Colin Hessel, Michael J. Morris, Toni K. Choueiri, Christian Scheffold, M. Dror Michaelson, Eric J. Small, Milan Mangeshkar
Publikováno v:
The Oncologist
The phase II CABOSUN trial compared cabozantinib with sunitinib as initial treatment in patients with advanced renal cell carcinoma of intermediate or poor risk. This article presents subgroup analyses by baseline patient characteristics.
Caboza
Caboza
Autor:
Bonne J. Adams, David F. McDermott, Charles P. Theuer, Zhenhua Yuan, Manoj A. Jivani, Guru Sonpavde, Ben K. Seon, Yingmiao Liu, Edwin M. Posadas, M. Dror Michaelson, Andrew B. Nixon, Toni K. Choueiri, Meghara K. Walsh
Publikováno v:
The Oncologist. 24:202-210
Background TRC105 is an IgG1 endoglin monoclonal antibody that potentiates VEGF inhibitors in preclinical models. We assessed safety, pharmacokinetics, and antitumor activity of TRC105 in combination with axitinib in patients with metastatic renal ce
Autor:
Darren R. Feldman, Toni K. Choueiri, Joel Picus, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Shaker R. Dakhil, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Eric J. Small, Susan Halabi, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 35:591-597
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cab
Autor:
Ulka N. Vaishampayan, Lauren C. Harshman, Rana R. McKay, David F. McDermott, Sabina Signoretti, Guillermo de Velasco, Toni K. Choueiri, Meghara K. Walsh, Joaquim Bellmunt, Michelle S. Hirsch, Jonathan E. Rosenberg, Christopher Sweeney, Lillian Werner, Eliezer M. Van Allen
Publikováno v:
Cancer. 122:2389-2398
Background The phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is dysregulated in patients with metastatic renal cell carcinoma (mRCC). Buparlisib is a pan-PI3K inhibitor with activity in advanced solid tumors. T
Autor:
Darren R. Feldman, Milan Mangeshkar, M. Dror Michaelson, Shaker R. Dakhil, Ben L. Sanford, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Joel Picus, Susan Halabi, Colin Hessel, Toni K. Choueiri, Olwen Hahn, Michael J. Morris, Christian Scheffold, Eric J. Small
Publikováno v:
European journal of cancer (Oxford, England : 1990)
Background The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point of improving progression-free survival (PFS) as as
Autor:
Toni K. Choueiri, Sabina Signoretti, Meghara K. Walsh, Rana R. McKay, Xiao X. Wei, Ronan Flippot, Eliezer M. Van Allen, Lauren C. Harshman, Abdallah Flaifel, Kathryn P. Gray, Katy Gundy, John A. Steinharter, Ulka N. Vaishampayan, Bradley Alexander McGregor
Publikováno v:
Journal of Clinical Oncology. 37:4583-4583
4583 Background: NccRCC and ccRCCsd are aggressive tumors associated with poor prognosis and response to therapy. Combination strategies co-targeting VEGF signaling and inhibitory immune checkpoints are highly active in clear-cell renal cell carcinom
Autor:
Mark Pomerantz, Laura Polacek, Susanna Jacobus, Atish D. Choudhury, Christopher Sweeney, Meghara K. Walsh, Judith Prisby, Rana R. McKay, Toni K. Choueiri, Lillian Werner, Amanda Fredericks Pace, Mary-Ellen Taplin, Hannah Mills
Publikováno v:
Journal of Medical Internet Research
Background: The pace of drug discovery and approvals has led to expanding treatments for cancer patients. Although extensive research exists regarding barriers to enrollment in oncology clinical trials, there are limited studies evaluating processes
Autor:
Bradley Alexander McGregor, Ulka N. Vaishampayan, Kathryn J. Gray, Lauren C. Harshman, Abdallah Flaifel, Rana R. McKay, Meghara K. Walsh, Toni K. Choueiri, Sabina Signoretti, David A. Braun, John A. Steinharter, Eliezer VanAllen, Xiao X. Wei
Publikováno v:
Journal of Clinical Oncology. 37:548-548
548 Background: NccRCC and sccRCC have historically been underrepresented in clinical trials. Even with targeted therapy, most patients have inferior survival compared to clear cell renal cell carcinoma. The combination of atezolizumab and bevacizuma
Autor:
Darren R. Feldman, Ben L. Sanford, Shaker R. Dakhil, Meghara K. Walsh, M. Dror Michaelson, Thomas Olencki, Toni K. Choueiri, Susan Halabi, Joel Picus, Daniel J. George, Colin Hessel, Olwen Hahn, Milan Mangeshkar, Michael J. Morris, Eric J. Small, Christian Scheffold
Publikováno v:
European Journal of Cancer. 103:287